Cognition Therapeutics Inc
CGTX
Company Profile
Business description
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Contact
2500 Westchester Avenue
PurchaseNY10577
USAT: +1 412 481-2210
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
25
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,815.30 | 5.00 | -0.06% |
| CAC 40 | 7,779.51 | 49.78 | -0.64% |
| DAX 40 | 24,039.35 | 215.96 | -0.89% |
| Dow JONES (US) | 44,371.51 | 279.13 | -0.63% |
| FTSE 100 | 8,957.18 | 16.06 | 0.18% |
| HKSE | 24,250.43 | 110.86 | 0.46% |
| NASDAQ | 20,585.53 | 45.14 | -0.22% |
| Nikkei 225 | 39,459.62 | 110.06 | -0.28% |
| NZX 50 Index | 12,678.69 | 7.99 | -0.06% |
| S&P 500 | 6,259.75 | 20.71 | -0.33% |
| S&P/ASX 200 | 8,570.40 | 9.70 | -0.11% |
| SSE Composite Index | 3,519.65 | 9.47 | 0.27% |